1. Home
  2. LIXT vs HSDT Comparison

LIXT vs HSDT Comparison

Compare LIXT & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • HSDT
  • Stock Information
  • Founded
  • LIXT 2005
  • HSDT N/A
  • Country
  • LIXT United States
  • HSDT United States
  • Employees
  • LIXT N/A
  • HSDT N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • LIXT Health Care
  • HSDT Health Care
  • Exchange
  • LIXT Nasdaq
  • HSDT Nasdaq
  • Market Cap
  • LIXT 2.2M
  • HSDT 2.5M
  • IPO Year
  • LIXT N/A
  • HSDT N/A
  • Fundamental
  • Price
  • LIXT $4.00
  • HSDT $8.05
  • Analyst Decision
  • LIXT
  • HSDT Hold
  • Analyst Count
  • LIXT 0
  • HSDT 1
  • Target Price
  • LIXT N/A
  • HSDT N/A
  • AVG Volume (30 Days)
  • LIXT 6.2M
  • HSDT 237.7K
  • Earning Date
  • LIXT 08-07-2025
  • HSDT 08-11-2025
  • Dividend Yield
  • LIXT N/A
  • HSDT N/A
  • EPS Growth
  • LIXT N/A
  • HSDT N/A
  • EPS
  • LIXT N/A
  • HSDT N/A
  • Revenue
  • LIXT N/A
  • HSDT $434,000.00
  • Revenue This Year
  • LIXT N/A
  • HSDT N/A
  • Revenue Next Year
  • LIXT N/A
  • HSDT $75.13
  • P/E Ratio
  • LIXT N/A
  • HSDT N/A
  • Revenue Growth
  • LIXT N/A
  • HSDT N/A
  • 52 Week Low
  • LIXT $0.64
  • HSDT $8.00
  • 52 Week High
  • LIXT $4.45
  • HSDT $1,200.00
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 80.89
  • HSDT 21.35
  • Support Level
  • LIXT $2.02
  • HSDT $8.21
  • Resistance Level
  • LIXT $4.25
  • HSDT $10.70
  • Average True Range (ATR)
  • LIXT 0.54
  • HSDT 1.47
  • MACD
  • LIXT 0.30
  • HSDT 6.62
  • Stochastic Oscillator
  • LIXT 96.99
  • HSDT 0.45

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About HSDT Helius Medical Technologies Inc. (DE)

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Share on Social Networks: